Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vaccinex (NASDAQ:VCNX)

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer

Related Keywords

United States ,Germany ,Vaccinex Rochester ,Albertd Friedberg ,John Mullaly ,Maurice Zauderer ,Alzheimer Association ,Vaccinex Inc ,Co Inc ,Merck Co ,Coherus Biosciences Inc ,Exchange Commission ,University Of Rochester Cancer Center ,Lifesci Advisors ,Merck Kgaa ,University Of Rochester ,Moffitt Cancer Center ,Wilmot Cancer Institute ,Pfizer Inc ,Alzheimer Drug Discovery Foundation ,Merck Kga ,Development Expenses ,Nasdaq ,Platform Technology ,Merck Sharp Dohme Corp ,Disease Achieves Full ,Interim Results ,Drug Discovery Foundation ,Nature Medicine ,Neck Cancer ,Moffitt Cancer ,American Society ,Clinical Oncology ,Rochester Cancer Center ,Bayesian Optimal Interval ,Gateway Discovery ,Breast Cancer Study ,Surface Oncology ,Coherus Biosciences ,Three Months Ended June ,Cash Equivalents ,Chief Executive Officer ,Comprehensive Loss ,Merck Sharp ,Dohme Corp ,Sci Advisors ,Consolidated Balance Sheets ,